BPC-157 vs TB-500: A Research Comparison

This page compares two names that are often mentioned together, as laboratory materials and as subjects of published preclinical research. It is not a ranking, and it makes no statement about use in people. Identity data come first, because that is where TB-500 most often causes confusion. All masses are average masses in g/mol.

BPC-157 is a defined sequence, GEPPPGKPADDAGLV, 15 residues long ^[1]. In the sources cited here the name corresponds to a single sequence.

TB-500 is not like that. It is a product label, not a systematic chemical name. In the analytical literature it is a short synthetic peptide, N-acetylated LKKTETQ, which corresponds to residues 17-23 of human thymosin beta-4 ^[5][8]. One study used HPLC with high-resolution mass spectrometry to identify this peptide in a product labelled TB-500, and also synthesised it ^[5]. A second analytical paper, which developed a mass-spectrometric method to detect TB-500 and its metabolites in horse urine and plasma, describes TB-500 as a synthetic version of a region of thymosin beta-4 with artificial acetylation of the N-terminus ^[8]; the mature protein carries its own N-terminal acetyl group on its first serine ^[6]. PubChem lists TB-500 among the synonyms of the fragment record, and the 29 synonyms listed for full-length thymosin beta-4 do not include it ^[2][3].

Database usage is less consistent. A chemical-database entry for thymosin beta 4 acetate (CAS 77591-33-4, C212H350N56O78S, average mass 4963.5) lists TB500 and TB-500 among its synonyms ^[4], whereas PubChem attaches both to the fragment record, as above. The two materials differ about 5.6-fold in mass. One name therefore appears on two different molecules. For transparency, the specification Full Spec Peptides publishes for its own TB-500 is the full-length form (CAS 77591-33-4, C212H350N56O78S, 4963.5 g/mol); as with any supplier's material, the measured mass on the lot COA is what confirms it.

Two smaller points can cause confusion when reading papers. The first is numbering. In UniProt's numbering, which counts the initiator methionine that is removed from the mature protein, the same residues fall at positions 18-24 (and the N-acetylserine at position 2), while papers using conventional 1-43 numbering say 17-23 ^[6][5]. The second is boundaries. Mutational mapping describes the actin-binding hexapeptide motif as residues 17-22 (LKKTET) ^[18], whereas a later review refers to the central actin-binding domain as residues 17-23 ^[19]. The edges of the motif are drawn slightly differently from source to source.

That leaves molecular mass as the deciding fact. Full-length thymosin beta-4 is roughly 3.5 times the mass of BPC-157, and the acetylated fragment is lighter than BPC-157, at about 63% of its mass ^[1][3][2]. A mass measurement therefore separates all three materials cleanly, and a COA that reports a measured mass lets you compare it with the values in the table. One caution: a quoted mass may be an average or a monoisotopic value, and the two differ slightly. The figures here are average masses.

HPLC does not, on its own, establish identity. It reports purity and retention behaviour, and the distinction is explained in HPLC vs LC-MS. How to find and read the identity section of a certificate is covered in How to read a peptide COA, and peptide COA red flags lists common gaps.

Where the BPC-157 literature has been systematically counted, it is overwhelmingly preclinical. A 2025 systematic review searched PubMed, Cochrane and Embase to June 2024, identified 544 articles dating from 1993 to 2024, and included 36 studies, of which 35 were preclinical (animal or cell-based) ^[11].

The origin of the compound is part of the record, and it is a reported one. In an early overview paper (1993), the authors described a gastric-juice peptide of relative molecular mass about 40,000, which they named BPC and reported as recently isolated, and characterised a 15-amino-acid fragment (BPC 157) that they thought essential for the peptide's activity ^[7]. This page does not rely on any independent characterisation of the parent protein, so the phrase 'fragment of a gastric-juice protein' is best read as that paper's description.

What the studies modelled falls into three broad groups.

• Tendon, muscle, ligament and bone models. The systematic review tabulated rat Achilles and quadriceps tendon transection models, rat muscle transection, crush and corticosteroid-impaired models, a rat medial collateral ligament transection model, a rabbit bone-nonunion model, a rat adjuvant polyarthritis model, and cultured rat tendon explants and fibroblasts. Male Wistar rats were the predominant animal ^[11].
• Ischemia-reperfusion models. A 2026 critical review covered rodent studies in skeletal muscle, hippocampal, intestinal and hepatic models ^[12].
• Isolated tissue and cell signalling. A 2020 study using isolated rat aortic rings and cultured endothelial cells reported endothelium- and nitric-oxide-dependent relaxation of the rings, nitric-oxide generation in the cells, and phosphorylation of Src, caveolin-1 and eNOS in the presence of BPC 157, with reduced caveolin-1-eNOS binding ^[13].

The last item is an observation in isolated tissue and cell culture. It describes a signalling association. The 2026 critical review describes a context-dependent interaction between BPC-157 and nitric-oxide signalling as consistent with the experimental observations, but says these associations do not establish a single causal NO-dependent pathway in ischemia-reperfusion injury, because direct pathway-intervention experiments remain limited ^[12].

Thymosin beta-4 has a longer biochemical record. It was first sequenced in 1981 from calf thymus: 43 residues with an acetyl-blocked N-terminus ^[9]. It was later shown to share its sequence with Fx, an actin-sequestering peptide from human platelets ^[10].

Its best-documented property is biochemical. It forms a 1:1 complex with monomeric (G) actin and inhibits actin polymerisation ^[10], and a review describes it as the major actin-sequestering molecule in eukaryotic cells ^[19]. Mutational mapping with synthetic full-length variants showed that actin binding involves two separate regions, an N-terminal segment (residues 1-16) and the hexapeptide motif LKKTET (residues 17-22), with lysines 14 and 18 important for contact ^[18].

One review covers animal-model work in dermal, corneal and cardiac settings ^[17], and another maps activities to short active-site sequences, including an N-terminal site and a region containing LKKTETQ ^[19]. A 2004 study reported that thymosin beta-4 increased myocardial and endothelial cell migration in the embryonic heart (a property retained in postnatal cardiomyocytes) and increased survival of cultured embryonic and postnatal cardiomyocytes. The same study reported that thymosin beta-4 formed a complex with PINCH and integrin-linked kinase that activated Akt, and it examined a mouse coronary-artery-ligation (myocardial injury) model ^[15].

Genetic work complicates the picture. Global knockout mice were reported to be born at expected ratios with normal heart and blood-vessel formation and, as adults, cardiac function and capillary density indistinguishable from controls; cardiac-specific knockouts showed no phenotype, in contrast to earlier cardiac shRNA-knockdown reports of embryonic lethality ^[16]. A 2013 follow-up from the same group reported no embryonic hemorrhaging, altered mural-cell development or lethality in global knockouts, and no embryonic lethality in endothelial-specific knockouts, in contrast to another group's report of vascular defects and partial embryonic lethality in a germline-null line and an endothelial shRNA-knockdown line ^[20]. The abstract of that follow-up is the only source consulted here for the other group's results.

Most of the biological work cited here used full-length thymosin beta-4. The N-acetylated fragment labelled TB-500 appears mainly in analytical papers of identity, metabolism and detection ^[5][8][14]. A 2024 paper notes that biological functions have been reported for the unacetylated peptide LKKTETQ, but states that the biological effects of TB-500 itself have not been documented ^[14]. Findings from the full-length protein cannot be assumed to carry over to a seven-residue piece of it.

Limitations come first here, because they decide how any of the studies above should be read. For BPC-157:

• Preclinical in the main. Of the 36 studies in the systematic review, 35 were preclinical and one was clinical ^[11]. The one clinical study is not summarised here, and this page describes no human findings. The review's search closed on 3 June 2024 ^[11]. A few small human reports have appeared in the literature since, and this page does not summarise them ^[21]. There is no established human safety profile.
• Heterogeneous, and graded as lower-level evidence. The review's authors stated that heterogeneity in study design, objectives and measured end points restricted their ability to conduct a quantitative meta-analysis, and described the included studies as level IV and V evidence ^[11]. The critical review of ischemia-reperfusion studies likewise describes a heterogeneous evidence base, limited independent and model-specific replication and incomplete risk-of-bias reporting, and describes BPC-157 as a hypothesis-generating candidate for further preclinical research ^[12].
• Authorship. A date-stamped PubMed search on 6 October 2026 for BPC 157, BPC-157 or BPC157 in title or abstract returned 226 records. Of these, 175 (77%) list Sikiric P or Seiwerth S, two authors of the 1993 overview paper ^[7], among their authors, and 150 (66%) have one of them as first or last author ^[21]. None of the 226 records carries a Clinical Trial or Randomized Controlled Trial publication type, which does not mean that no human reports exist. This describes authorship, not quality. Counts change as records are added, name matching is imperfect, and the critical review explicitly declined to regard author overlap alone as evidence that studies are not independent ^[12].
• Independent work exists but is limited. Other groups have published on BPC-157, such as the 2020 aortic-ring study above ^[13], yet the critical review still describes independent and model-specific replication as limited ^[12].

For thymosin beta-4 and TB-500:

• Animal, cell-based and biochemical work only, here. The studies summarised above used animal models (including mouse studies ^[15][16][20]), cultured cells or cell-free biochemistry. The fragment papers are analytical; one of them detected TB-500 and its metabolites in horse urine and plasma samples ^[8].
• Groups disagree. Different knockout and knockdown studies reached different conclusions about the role of thymosin beta-4 in cardiac and vascular development ^[16][20].
• Material mismatch. The biology comes mainly from full-length thymosin beta-4, while the fragment labelled TB-500 is characterised mainly analytically ^[5][8][14]. A study of one cannot be assumed to describe the other.
• Two naming conventions. Papers, databases and catalogues use TB-500 for different molecules, so a finding attributed to 'TB-500' needs the exact material identified before it can be interpreted.

The two literatures overlap only loosely. Both include rodent models of injury, but species, assays and end points differ, and none of the sources cited here compares the two materials directly. This page summarises no human findings.

Compound overviews are at BPC-157 and TB-500. Certificates of analysis are listed at BPC-157 COA and TB-500 COA where a lot has been published, and the COA index covers the other materials. For the same side-by-side format applied to two other compounds, see Semax vs Selank, and see the research index for the full list.